194 related articles for article (PubMed ID: 37431609)
21. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
22. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
Sheshadri A; Goizueta AA; Shannon VR; London D; Garcia-Manero G; Kantarjian HM; Ravandi-Kashani F; Kadia TM; Konopleva MY; DiNardo CD; Pierce S; Zarifa A; Albittar AA; Zhong LL; Akhmedzhanov FO; Arain MH; Alfayez M; Alotaibi A; Altan M; Naing A; Mendoza TR; Godoy MCB; Shroff G; Kim ST; Faiz SA; Kontoyiannis DP; Khawaja F; Jennings K; Daver NG
Cancer; 2022 Jul; 128(14):2736-2745. PubMed ID: 35452134
[TBL] [Abstract][Full Text] [Related]
23. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary toxicity of systemic lung cancer therapy.
Long K; Suresh K
Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207
[TBL] [Abstract][Full Text] [Related]
25. Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the
Nishino M
AJR Am J Roentgenol; 2022 Jan; 218(1):19-27. PubMed ID: 33594904
[TBL] [Abstract][Full Text] [Related]
26. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
29. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
[TBL] [Abstract][Full Text] [Related]
30. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang L; Li B; Xu Y; Zou B; Fan B; Wang C; Wang L
Future Oncol; 2023 May; 19(16):1151-1160. PubMed ID: 37293787
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
[TBL] [Abstract][Full Text] [Related]
32. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
33. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
[TBL] [Abstract][Full Text] [Related]
34. The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports.
Mojsak D; Dębczyński M; Kuklińska B; Moniuszko-Malinowska A; Mróz RM
Am J Case Rep; 2022 Jun; 23():e936420. PubMed ID: 35648729
[TBL] [Abstract][Full Text] [Related]
35. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
36. Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis.
Jung J; Kim HY; Kim DG; Park SY; Ko AR; Han JY; Kim HT; Lee JS; Lee Y
Cancer Res Treat; 2021 Jan; 53(1):77-86. PubMed ID: 32777877
[TBL] [Abstract][Full Text] [Related]
37. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma.
Küçükarda A; Gökmen İ; Özcan E; Peker P; Akgül F; Çiçin İ
Immunotherapy; 2022 Apr; 14(6):395-399. PubMed ID: 35152716
[TBL] [Abstract][Full Text] [Related]
38. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.
Wang Y; Wang Y; Yu J; Meng X
Front Immunol; 2022; 13():998516. PubMed ID: 36189237
[TBL] [Abstract][Full Text] [Related]
39. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
40. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
Shannon VR
Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]